The company will continue to use the Avantra name for its proteomics portfolio, which includes the Avantra Biomarker System.
Courtagen CEO Brian McKernan said the name change reflects the company’s new strategic focus on developing advanced technologies in both genomic and proteomic areas and their commitment to bring additional needed technologies to the market.